News for ResMed Inc. (RSMDF)

Apnimed has announced encouraging results from its second pivotal Phase 3 clinical trial of AD109, a lead candidate for treating obstructive sleep apnea (OSA).

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ResMed (RMD) received a significant upgrade from RBC Capital on July 16, 2025. The analyst, Craig Wong-Pan, upgraded the stock's rating from

On July 16, 2025, Mizuho analyst Anthony Petrone updated his coverage on ResMed (RMD), maintaining the company's

On July 2, 2025, Peter Farrell, Director at ResMed Inc (RMD), sold 945 shares of the company. Following this transaction, the insider now owns 68,273 shares of

ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership. Read why RMD stock is a Strong Buy.

On June 4, 2025, Peter Farrell, Director of ResMed Inc (RMD), sold 2,000 shares of the company, according to a SEC Filing. Following this transaction, the insid

On June 2, 2025, Brett Sandercock, the Chief Financial Officer of ResMed Inc's subsidiary, sold 1,000 shares of ResMed Inc (RMD). Following this transaction, th

You may be concerned about the recent declines in AI stocks such as NVDA.

On May 20, 2025, Witte De, a Director at ResMed Inc (RMD), sold 2,000 shares of the company, as reported in a SEC Filing. Following this transaction, the inside

Below is the April 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update,

Resmed (RMD) has been designated as the Official Sleep Partner for the Qatar Airways British & Irish Lions Tour to Australia. In this role, Resmed will initiate

On May 7, 2025, Peter Farrell, Director at ResMed Inc (RMD), sold 2,000 shares of the company, according to a SEC Filing. Following this transaction, the inside

ResMed's acquisition of VirtuOx is set to advance its diagnostic capabilities. Analysts predict a potential 9.62% upside for ResMed stock. ResMed is

Resmed (RMD) has made a strategic move by acquiring VirtuOx, a prominent independent diagnostic testing facility. This acquisition underscores Resmed's dedicati

ResMed Inc (RMD) showcases robust revenue growth and improved gross margins in recent quarters.Investments in innovation and digital health solutions position

Shares of ResMed Inc (RMD) surged 11.28% in mid-day trading on Apr 24. The stock reached an intraday high of $239.00, before settling at $238.64, up from it

ResMed Inc (RMD) has recently been in the spotlight, drawing interest from investors and financial analysts due to its robust financial stance. With shares curr

U.S. stocks were higher, with the Nasdaq Composite gaining around 300 points on Thursday. Shares of Texas Instruments Incorporated TXN rose sharply during Thur...